

FIGURE 1

Subjective Drug Effects Scale: Liking This Feeling
Maximum Change from Baseline (PDmax)
Population: Valid for Pharmacodynamic
Treatment-by-Period Means




FIGURE 2

Subjective Drug Effects Scale: Liking This Feeling
Area Under the Curve for Change from Baseline (PDmax)
Population: Valid for Pharmacodynamic
Treatment-by-Period Means




FIGURE 3

Subjective Drug Effects Scale: Good Effects
Maximum Change from Baseline (PDmax)
Population: Valid for Pharmacodynamic
Treatment-by-Period Means




FIGURE 4

Subjective Drug Effects Scale: Good Effects
Area Under the Curve for Change from Baseline (AUC)
Population: Valid for Pharmacodynamic
Treatment-by-Period Interaction





FIGURE 5


Subjective Drug Effects Scale: Feeling Sick
Maximum Change from Baseline (PDmax)
Population: Valid for Pharmacodynamic
Treatment-by-Period Means



Treatment: ●-●-● NTX placebo ○-○-○ 0.25 mg NTX ○-○-○ 0.50 mg NTX

FIGURE 6


Subjective Drug Effects Scale: Feeling Sick
Area Under the Curve for Change from Baseline (AUC)
Population: Valid for Pharmacodynamic
Treatment-by-Period Means



Treatment: ●-●-● NTX Placebo ○-○-○ 25 mg NTX ○-○-○ 50 mg NTX

FIGURE 7

Subjective Drug Effects Scale: Bad Effects
Maximum Change from Baseline (PDmax)
Population: Valid for Pharmacodynamic
treatment-by-Period Means



Treatment:


●-●-● NTX Placebo

○-○-○ 0.0025 mg NTX

◇-◇-◇ 0.0050 mg NTX

FIGURE 8

Subjective Drug Effects Scale: Bad Effects
Area Under the Curve for Change from Baseline (AUC)
Population: Valid for Pharmacodynamic
Treatment-by-Period Means



Treatment: ◆- - - NTX Placebo ●- - - 0.5 mg NTX

FIGURE 9

Subjective Symptom Rating Scale: Antagonist
Maximum Change from Baseline (PDmax)
Population: Valid for Pharmacodynamic
Treatment-by-Period Means





FIGURE 10

Subjective Symptom Rating Scale: Antagonist
Area Under the Curve for Change from Baseline (AUC)
Population: Valid for Pharmacodynamic
Treatment-by-Period Means



Treatment: ●---● NTX placebo ○---○ 0.5 mg NTX

FIGURE 11

Pupil Diameter (mm)
Maximum Change from Baseline (PDmax)
Population: Valid for Pharmacodynamic
Treatment-by-Period Means





FIGURE 12

Pupil Diameter (mm)
Area Under the Curve for Change from Baseline (AUC)
Population: Valid for Pharmacodynamic
Treatment-by-Period Means



Treatment: ●---● NTX Placebo ○---○ 25 mg NTX ○---○ 50 mg NTX

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.